Potential AstraZeneca and BMS Merger: A $400 Billion Pharmaceutical Giant
Reports indicate that pharmaceutical giants AstraZeneca and Bristol-Myers Squibb (BMS) are in talks regarding a potential merger. If successful, the deal could create a combined entity with a market capitalization of nearly $400 billion, marking one of the largest transactions in industry history.
The Financial Times reported yesterday after trading hours that pharmaceutical companies AstraZeneca and Bristol-Myers Squibb (BMS) are in talks for a potential merger. AstraZeneca is traded at a market cap of 196 billion pounds ($264 billion) on the London Stock Exchange, while BMS is traded at a market cap of $133 billion on the New York Stock Exchange.
If the merger is welcomed by the market and the companies maintain their market value, the combined entity could become a giant worth nearly $400 billion. Such a deal could be one of the largest ever in the pharmaceutical industry. Both companies have traded with gains over the past year: BMS shares rose 44% and AstraZeneca shares rose 13%, continuing a five-year streak of strong performance.
Antitrust Considerations
Antitrust regulations could pose a challenge, as both companies operate in relatively similar fields. At AstraZeneca, most of the profit comes from the oncology sector, which generated $25 billion in revenue in 2025 out of a total revenue of about $59 billion. It also has significant operations in cardiology, kidney disease, and metabolism. BMS also holds strong positions in cardiology, hematology, and oncology, recording revenue of $48 billion in 2025. A merger might require the divestment of certain products, although most are not direct competitors.
AstraZeneca maintains a broad product pipeline, primarily in oncology. BMS needs to replace several significant products nearing patent expiration, including Eliquis, its largest product with $14 billion in revenue, and the cancer immunotherapy drug Opdivo. The company is pinning its hopes on new products, including Cobenfy for schizophrenia, which originated from the $14 billion acquisition of Karuna, founded by former Israeli Dafna Zohar. The product recorded $155 million in revenue in 2025, its first full year, and its potential as a bestseller remains to be seen.
AstraZeneca listed on the New York Stock Exchange last February to strengthen its position in the American market. It has been expanding manufacturing capacity in the USA, partly due to demands from US President Donald Trump that pharmaceutical companies transfer more production capacity to the country. Acquiring BMS could allow it to accelerate its American presence. For Bristol, this represents an opportunity to mitigate dependence on an uncertain product pipeline.
Both companies have made acquisitions in recent years, but not mergers of this magnitude. For BMS, the $14 billion acquisition of Karuna was a major move, following the 2020 purchase of MyoKardia. AstraZeneca acquired Alexion in 2021 for $40 billion and has not made an acquisition of similar scale since.
The companies have not yet responded to the Financial Times report, and their shares have not yet reacted to the news.
